logo-loader
RNS
NMC Health PLC

NMC Health Plc - Board Changes

RNS Number : 7692H
NMC Health Plc
26 March 2020
 

26 March 2020

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF THE MARKET ABUSE REGULATION NO. 596/2014 ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

NMC Health plc

 

(the "Company" or "NMC")

 

Board Changes

 

NMC Health plc (LSE: NMC), the leading private healthcare operator in the Gulf Cooperation Council (GCC) with international services across 19 countries, today announces a change of Chairman of the Board with immediate effect.

 

Mr H. J. Mark Tompkins, Non-Executive Chairman

 

The Board confirms that following a period of ill health over the last few weeks which has prevented him from participation in Board activities, Mr H. J. Mark Tompkins has left the Board and ceased to be Chairman and a Director of the Company with immediate effect. This decision was taken as a result of the difficult period which NMC has faced and a desire of the remaining Board members to focus on the challenges ahead for the Company.

 

Mark Tompkins has been Chairman since prior to the Company's IPO in 2012. The Board would like to thank Mark for his significant commitment to NMC during his tenure as Chairman.

  

Mr Faisal Belhoul, appointed as Executive Chairman

 

The Board has also decided today to appoint Mr Faisal Belhoul as Executive Chairman of the Company. The Board has decided that the appointment of an Executive Chairman based in the UAE is appropriate given the challenging period the Company is facing at the current time as it reviews previous financial irregularities; discusses its debt position with its lenders; focuses on preserving value for its stakeholders; and continues to deliver outstanding levels of care to patients. The Board considers this appointment as strategic to ensure that NMC's position as the leading private healthcare provider, and a key component of healthcare infrastructure in the GCC, is protected.

 

Mr Belhoul is a founder of Ithmar Capital Partners and currently serves as its Chairman. He is also a founder of Amanat Holdings PJSC, which is one of the GCC's largest integrated healthcare and education publicly listed investment company where he served as its chairman from December 2014 to December 2017. In addition, Mr Belhoul was chairman of the board for a number of business groups and associations, including the UAE Private Hospitals Council, the UAE Private School Council, the Pharmaceutical and Healthcare Equipment Business Group of the Dubai Chamber of Commerce and Industry (DCCI). He served previously as a board member of Al Noor, the FTSE 250 healthcare company, whose listing Mr Belhoul led on the London Stock Exchange (LSE) in June 2013.

 

Ithmar Capital has disclosed a holding in NMC of 9%, which was announced via RNS on 25 March 2020.  The Board is satisfied that Ithmar Capital's holding in NMC and Mr Belhoul's other hospital interests do not present a conflict of interest with his appointment as Executive Chairman.

 

 

Mr Belhoul is a board member of the DCCI by decree from the Ruler of Dubai as well as being a member of the Young Presidents Organization (YPO). In 2007, he was recognized by Arabian Business as one of the top 100 Executives in the Gulf region. Educated in the USA, where he studied Manufacturing Engineering at Boston University and subsequently completed a senior executive leadership program with Harvard University. 

 

Commenting on the appointment, Michael Davis, Interim CEO of NMC said:

 

"I am delighted that NMC has been able to attract a proven leader such as Faisal to assist our turnaround.  Faisal's experience and local contacts will be of great value to the company in its present circumstances.  I look forward to working with Faisal and the Board to continue to deliver outstanding levels of care to patients at this critical time."

 

Mr Belhoul commented:

 

"I recognise the challenges faced by NMC at the moment, but also see the underlying value of a business with its place at the heart of the infrastructure of the GCC.  NMC has some outstanding assets and people working to provide the highest standards of care.  My role will be to work with them and to focus on the governance of the business to enable it to deliver value to its stakeholders."

 

There is no additional information in respect of Mr Belhoul which is required to be notified for the purposes of Listing Rule 9.6.13.

 

 

Enquiries:

 

NMC Health plc


Simon Watkins, Group Company Secretary

+44 (0) 203 205 7313

Asjad Yahya, Head of Investor Relations

+971 (0) 56 219 0975

 

 

FTI Consulting


Edward Bridges / Simon Conway / Victoria Foster Mitchell

+44 (0)20 3727 1000

Shane Dolan

+971 (0)4 437 2100

 

About NMC Health

 

NMC is one of the leading private healthcare operators in the Gulf Cooperation Council ("GCC") with an international network of multi-specialty inpatient and outpatient clinics and hospitals, specialized maternity and fertility clinics, and long-term care homes hospitals across nineteen countries. NMC also ranks as one of the top two in-vitro fertilisation operators globally. The NMC Health group is recognised as a leading provider of long-term medical care in the UAE through its subsidiary ProVita. Pursing a selective international expansion programme since 2016, NMC has total capacity of 2,207 licensed beds across its network. Moreover, the recent formation of a joint venture with GOSI/Hassana Investment Company provides a solid platform for continued growth in the GCC region's largest healthcare market. The NMC Health group treated over 7.5 million patients in 2018. The NMC Health group is also a leading UAE supplier of products and consumables coming from healthcare related products. NMC reported revenues of US$2.1 billion for the year ended 31 December 2018.

 

In April 2012, NMC was listed on the Premium Segment of the London Stock Exchange.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAPPURUWUPUGQQ
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read